COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00179777




Registration number
NCT00179777
Ethics application status
Date submitted
10/09/2005
Date registered
16/09/2005
Date last updated
30/07/2021

Titles & IDs
Public title
TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk
Scientific title
TRIGR - Trial to Reduce IDDM in the Genetically at Risk
Secondary ID [1] 0 0
U01HD040364
Secondary ID [2] 0 0
MCT-49395
Universal Trial Number (UTN)
Trial acronym
TRIGR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 1 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Hydrolysed infant formula
Other interventions - Nonhydrolysed infant formula

Experimental: Hydrolysed infant formula - Hydrolysed infant formula

Placebo Comparator: Nonhydrolysed infant formula - Nonhydrolysed cow's milk based infant formula


Other interventions: Hydrolysed infant formula
Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.

Other interventions: Nonhydrolysed infant formula
Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Type 1 Diabetes Mellitus - Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.
Timepoint [1] 0 0
12 and 18 months and annually from 2 years up to 14 years
Secondary outcome [1] 0 0
Number of Participants With Diabetes Associated Autoantibodies - Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years
Timepoint [1] 0 0
3, 6, 9, 12, 18 months and annually from 2 years up to 14 years

Eligibility
Key inclusion criteria
- Biological parent and/or full (not half) sibling of the newborn infant had type 1
diabetes as defined by the World Health Organization

- The infant's parent or legal guardians gave signed consent to participate
Minimum age
No limit
Maximum age
7 Days
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- An older sibling of the newborn infant had been included in the TRIGR intervention

- Multiple gestation

- The parents were unwilling or unable to feed the infant cow's milk based products for
any reason (e.g., religious, cultural).

- The newborn infant had a recognizable severe illness such as those due to chromosomal
abnormality, congenital malformation, respiratory failure needing assisted
ventilation, enzyme deficiencies, etc.

- The gestational age of the newborn infant was less than 35 weeks.

- The infant was older than 7 days at randomization.

- Inability of the family to take part in the study (e.g. the family has no access to
any of the Study Centers, the family has no telephone).

- The infant had received any infant formula other than Nutramigen prior to
randomization.

- No HLA sample drawn before the age of 8 days.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Pennsylvania
Country [3] 0 0
Canada
State/province [3] 0 0
Ontario
Country [4] 0 0
Czechia
State/province [4] 0 0
Prague
Country [5] 0 0
Estonia
State/province [5] 0 0
Tartu
Country [6] 0 0
Finland
State/province [6] 0 0
Helsinki
Country [7] 0 0
Germany
State/province [7] 0 0
Hannover
Country [8] 0 0
Hungary
State/province [8] 0 0
Budapest
Country [9] 0 0
Italy
State/province [9] 0 0
Sardinia
Country [10] 0 0
Italy
State/province [10] 0 0
Rome
Country [11] 0 0
Luxembourg
State/province [11] 0 0
Luxembourg
Country [12] 0 0
Netherlands
State/province [12] 0 0
Rotterdam
Country [13] 0 0
Poland
State/province [13] 0 0
Wroclaw
Country [14] 0 0
Spain
State/province [14] 0 0
Vizcaya
Country [15] 0 0
Spain
State/province [15] 0 0
Madrid
Country [16] 0 0
Sweden
State/province [16] 0 0
Linkoping
Country [17] 0 0
Switzerland
State/province [17] 0 0
Zurich

Funding & Sponsors
Primary sponsor type
Other
Name
University of Helsinki
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
US Congress
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Government body
Name [2] 0 0
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Canadian Institutes of Health Research (CIHR)
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Juvenile Diabetes Research Foundation
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
European Community (EC)
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
European Foundation for the Study of Diabetes
Address [6] 0 0
Country [6] 0 0
Other collaborator category [7] 0 0
Commercial sector/Industry
Name [7] 0 0
Mead Johnson Nutrition
Address [7] 0 0
Country [7] 0 0
Other collaborator category [8] 0 0
Other
Name [8] 0 0
Academy of Finland
Address [8] 0 0
Country [8] 0 0
Other collaborator category [9] 0 0
Other
Name [9] 0 0
Diabetes Research Foundation, Finland
Address [9] 0 0
Country [9] 0 0
Other collaborator category [10] 0 0
Other
Name [10] 0 0
Dutch Diabetes Research Foundation
Address [10] 0 0
Country [10] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to
conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The
TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because
their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to
breast feed their infants for as long as possible. Prior to birth, the child was randomly
assigned to receive one of two infant formulas, should formula be required prior to 8 months
of age. The study determined whether weaning to a possibly protective infant formula
decreases these children's chances of developing diabetes - as it does in the animal models
for diabetes.
Trial website
https://clinicaltrials.gov/show/NCT00179777
Trial related presentations / publications
Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Riikjärv MA, Ormisson A, Ludvigsson J, Dosch HM, Hakulinen T, Knip M; National TRIGR Study Groups. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia. 2005 May;48(5):829-37. Epub 2005 Apr 19. Erratum in: Diabetologia. 2005 Aug;48(8):1676. Riikjärv, MA [added]; Ormisson, A [added]; Ludvigsson, J [added]; Dosch, HM [added]; Hakulinen, T [added]; Knip, M [added].
TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes. 2007 Jun;8(3):117-37.
Åkerblom HK, Knip M, Becker D, Dosch H-M, Dupré J, Ilonen J, Krischer JP and the TRIGR Study Group. The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes. Immun, Endoc, Metab Agents in Med Chem 7:251-263, 2007.
Public notes

Contacts
Principal investigator
Name 0 0
Mikael Knip, MD
Address 0 0
University of Helsinki
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications